Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Vitrolife, Audiocast, Q4'25

By Inderes2/3/2026, 9:00 AM
Vitrolife

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Bronwyn Brophy O’Connor
00:01 - 08:10

Good morning, everyone, and welcome to the Vitrolife AB Group Q4 report. I'll now move you to the first slide of the presentation. Let me start with the highlights. We delivered 6% organic growth in local currencies, excluding discontinued business, beating our own internal forecasts for the quarter, supported by strong top-line growth in the Americas, again driven by North America. I should also call out that APAC also performed very well in the quarter, with 10% organic growth in local currencies. And the third point that I would like to highlight is that following a strategic review of our genetic services business, we announced a restructuring program in December. This will allow us to focus on the key tests and markets with stronger prospects for profitable growth. I'll now move you on to the next slide, please, and take you through the key highlights. So sales in the fourth quarter were 891 million SEK, an organic growth in local currencies of 6%, as I mentioned, but significantly impacted by -10% from currency effects. Gross margin was 58.6% when adjusted for the restructuring. This was a decrease versus Q4 2024, which was exceptionally strong. Additional factors impacting the gross margin include a currency impact that constitutes the majority of the effect, and the regional mix. So you will see in the coming slides, we are increasingly having a greater percentage of our revenue coming from Americas. And then we also have a mix effect within consumables in APAC, where we had a targeted campaign in disposable devices moving down. EBITDA for the quarter was 251 million SEK, equating to an EBITDA margin of 28.2%. We also have a significant negative currency impact here, just under 3%. Regional mix and product mix, as I mentioned also in relation to margin, is playing a role. And we do have higher OpEx here due to strategic investments that we made in sales and marketing in North America. Of course, that also helped us to drive growth there, as well as in IT, where we have made investments to support our customer journey and enable us to drive growth in North America. I'd like then to comment on the operating cash flow 160 million SEK. Clearly here the starting point is lower for the reasons that I have just explained. Last year, we also had a positive effect from changes in net working capital. So then for the full year, we had organic growth in local currencies, excluding discontinued business, of 4%, and Pär, in his final slide of the financial section, will actually take you through the full year numbers in detail. Okay, moving on then please, to the sales and growth per geographical segment. So, I'll start with Americas where, as I said, we delivered 9% organic growth in local currencies, driven by a very strong performance in our key focus markets of North America. Americas, as you can now see, accounts for 34% of our revenue. Moving on then to EMEA, a challenging quarter for our EMEA region as we expected, due to a very strong technology quarter across the region in Q4 2024. I do want to highlight that Europe is performing well. However, genetic services in the Middle East is impacting the overall EMEA result. A great quarter in consumables across the region, with share gains in key focus markets, and EMEA now accounts for. As you can see there, 34% of total sales. Okay. Moving on then to APAC. We had strong growth in APAC, up 10%. Organic growth in local currencies in this region outperformed our internal expectations in both consumables and technologies. We'll move on now and take a deeper dive into each of the regions. Starting with market region, EMEA sales in EMEA were 333 million SEK, a decrease of 1% in local currencies. Excluding discontinued business, consumables delivered 11% growth, well above market growth levels, and this was driven by share gains in key focus markets where we've decided to double down. So you're really going to see that focus is the name of the game for us. As I previously mentioned, we were very challenged to deliver growth in technologies in this region due to the comps with last year. So this decline was forecasted and expected. What I am pleased with is the run rate. Revenue coming from the consumables part of technologies is performing strongly. Moving into Genetics then in the EMEA region. Genetics is performing very well in Europe. However, clinics in the Middle East have in-sourced activities to boost their income during the downturn from the geopolitical situation, and we don't expect this business to return. Typically, when clinics insource, it tends to stay that way. Moving on then to the Americas region. Americas. We had sales of 299 million SEK in Americas, with an organic growth of 9% in local currencies. We delivered strong growth across the entire portfolio in all markets in the region, which was great to see. The investments we have made in sales and marketing in North America are clearly paying off, and there is no doubt that we are taking share in this key region for the Vitrolife AB group, and we have been focusing the team on increasing the penetration of EmbryoScope, and we were delighted to see a 40% growth in technologies in this region in the quarter. Genetics also continued to perform well, driven by share gain momentum. Earlier in the year, we had taken quite a bit of share in North America, and that share gain momentum continued in Q4. I will now move you on to market region APAC and give you some more color on the performance here. So a strong finish to the year in our APAC region, with growth of 11% in local currencies, in consumables driven by share gains in disposable devices. Where we launched a targeted campaign, we delivered 13% growth in technologies as clinics finally released. Year-end budgets, thereby allowing for investments in capital purchases. So overall, a strong finish to the year after a tough first half in APAC. I will now hand you over to Pär, who will take you through further details on our geographical segments.

Pär Ihrskog
08:11 - 17:17

Thank you Bronwyn. We are now on page number nine in the deck, where I will provide more details of the geographical segments Americas, EMEA, and APAC. Starting with the Americas. On the left side, as we mentioned, sales amounted to 299 million, reflecting a 9% organic growth in local currencies and a -4% growth in SEK, negatively impacted by currency. Gross income amounted to 167 million, with a gross margin of 55.7%. This compares to last year's gross income of 171 million and a margin of 55.0, an improvement of 0.5% points, driven by the product mix. Despite being negatively impacted by other effects on the gross margin. Selling expenses for the quarter rose from 76 to 83 million, reflecting the ongoing investments in sales and marketing in the US. As previously announced, the market contribution for the quarter was 27.9%, compared to 30.5% last year, impacted by the increased strategic investment into sales and marketing capabilities. Let's move on to EMEA. And there we have a -7% decrease in local currencies and a -13% decrease in SEK, totaling 333 MSEK in sales. The sales were negatively impacted by currencies and the discontinued business. Excluding the discontinued business, sales decreased by 1% in local currencies. Gross income was 195 million, with a gross margin of 58.5%, compared to 245 million, with a margin of 63.9% last year, mainly driven by the restructuring reserve. Negative currency and product mix effects. The gross margin, excluding the restructuring, was 60.2%. Selling expenses increased from 82 million to 100 million SEK. And excluding the restructuring cost, selling expense amounted to 79 million SEK, which is in line with last year's level. Then the market contribution margin for the quarter was 28.4% compared to 42.4%, explained by restructuring and product mix. The adjusted market contribution was 36.4%. In APAC, sales amounted to 259 million, reflecting 10% organic growth in local currencies, but a 2% decrease in SEK, negatively impacted by currency. Gross income was 155 million, with a gross margin of 59.9%, which is lower than the previous year's gross income of 170 million SEK and a gross margin of 64.2%, a decline of 4.3 percentage points compared to the previous year, primarily due to negative impacts from currency and product mix within the consumables in APAC. The selling expenses increased from 40 million to 45 million SEK. The market contribution margin for the quarter was 42.5%, down from 49.1% last year, explained by a lower gross margin and somewhat higher OpEx in the quarter. Let's move to the next slide. On this slide, I will comment on the Q4 financial highlights, starting with net sales. As already mentioned, the sales amounted to 891 million compared to previous year, with sales of 959 million, corresponding to a 3% growth in local currencies, a 7% decrease in SEK, and a 6% positive organic growth in local currencies. Excluding discontinued business, the gross income amounted to 522 million, compared to 586 million previous year, corresponding to a gross margin of 58.0%, down from 61.1%. Q4 2024 was an exceptionally strong quarter from a margin perspective, adjusted for the restructuring, the margin for Q4 this year was 58.6, which is more in line with our historical performance. The drop in the margin is explained by mainly currency effect, but also regional mix effect and also the mix effect coming from the consumables in APAC. And then I move to EBITDA. All in all, this gives us an adjusted EBITDA of 251 million, compared to 337 million last year. As I just mentioned, this was an exceptionally strong quarter last year, and this gives us an EBITDA margin of 28.2% when adjusting for restructuring expenses compared to 35.1% last year. The drop in margin is explained by currency effect. Regional mix effect and mix effect within the Consumables in APAC. Okay, let's move to the next slide where I will go more into details on the operational expense development last year compared to this year. Last year we had an OpEx of 361 million, and this year we ended up at 378 million. And let me explain the bridge here. Then on the selling expense, we saw an increase. This is excluding impairment and restructuring reserve. So this is clean from those one-time bookings. The selling expense increased by 6 million, reflecting the investment we have done in North America in sales and marketing. The administrative expense saw a reduction of 2 million versus Q4 last year. We still have some increase in IT expenses here, but that has been offset by reductions in other administrative areas. So a positive net effect on the R&D. We saw an increase of 5 million in the quarter compared to last year, which is mainly a phasing effect. And the spending here is in line with our effort to increase our R&D expenses in preparation of new product launches. And on the other operating expenses in this one, we also have the FX effect from our revaluation of accounts receivable. And accounts payable had a negative effect in total. The drop in the margin is explained by mainly currency effect, but also regional mix effect and also the mix effect coming from the consumables in APAC. The drop in the margin is explained by mainly currency effect, but also regional mix effect and also the mix effect coming from the consumables in APAC. Then key financials. Here I will focus on the year to date column. Mainly. And the sales for the full year amounted to 3.5 billion, corresponding to a 2% growth in local currencies, a 5% decrease in SEK, and a 4% organic increase in local currencies. Excluding discontinued business, the gross margin decreased from 59.3 to 58.1, mainly due to currency effects. The adjusted gross margin is 58.2%. The EBITDA for the full year amounted to 949 million, compared to 1.1 billion, corresponding to an EBITDA margin of 27.6% versus 34.0% in the previous year. The adjusted EBITDA margin was 29.2% for the full year. And again, the decrease in demand is heavily impacted by currency effect, driven by a strengthened SEK against other currencies. The margin was also negatively affected by the increase in OpEx, which I explained is mainly selling expenses in North America and our IT investment. Net income amounted to 390 MSEK, compared to 540 MSEK the previous year, heavily impacted by the currency fluctuations. This gives an earnings per share of 2.89 compared to 3.78. Last year. On the operating cash flow, it amounted to 635 million for the full year, compared to 907 million the previous year. And the main reason is the underlying result. But also we had a negative impact on the changes in net working capital this year, explaining part of the difference. Our leverage Net Debt to EBITDA ended up at 0.7 compared to 0.7 previous year. The proposed dividend from the board is 1.10 SEK per share, which is the same as last year, and I will now hand over to you again, Bronwyn.

Bronwyn Brophy O’Connor
17:18 - 20:55

Thank you Pat. Moving on to the focus for 2026. And as always, we will focus on three key areas: growth, innovation, and operational excellence. And I'd like to start with growth. We will continue to drive share gains in key markets. And that's very important. We're not going to be all things to all people in key markets, leveraging the full breadth of the portfolio. I think one of the statistics that we've been tracking very closely is the percentage of customers who are now buying across consumables, technologies and genetic services, and this is trending up nicely. So the strategy of leveraging the full breadth is working and will continue to drive share gains using our portfolio position. The second point on growth is to accelerate the penetration of our combined EmbryoScope and lab control solutions. We've really doubled down here. That's why we're particularly happy with the 40% growth in North America in Q4. And it's really as a result of the combined EmbryoScope and Lab Control Solutions. The third point is very important. We have been investing in commercial excellence capabilities for the past 12 months. It improves our segmentation. It helps us to drive profitable growth. And back to the point around taking market share. We've been tracking this very closely now with much more advanced metrics than we had previously. So we will further leverage the commercial excellence capabilities in 2026 again to drive that profitable growth. Moving on then to innovation. We have prioritized the programs that will have the greatest impact and relevance for customers and patients. I think that's very important. And then we hear clinics and customers crying out for help with automation. So we will further develop and we continue to invest in our IVF platform. This will ultimately help clinics to automate, to scale and to drive efficiency. And actually, if you look at the integration that we now have between EmbryoScope and our witnessing solution, you can see the forays that we are making in that area in relation to operational excellence. We have invested in IT and digital capabilities. We need to make further investments there to improve the customer journey. This really also helped us in North America last year, and some of the key focus markets in APAC and Europe, and it also helps to increase our efficiency and focus. Another focus area in relation to operational excellence heading into 2026 is we want to drive improvements in our internal processes and workflows to optimize our cost base. And then, as you know, the Vitrolife AB group doesn't like to issue guidance, but we just wanted to give an opinion on the macroeconomic conditions. As we turn the corner and are now into 2026, we do expect market conditions to return to more normal levels this year, thereby providing greater opportunities for us to drive profitable growth. So this will be the focus for the company in 2026. And with that, I think we can now move into Q&A. Thank you very much for your attention.

Operator
20:58 - 21:21

If you wish to ask a question, please dial Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. Please start by asking one question, followed by a follow-up question. It's then fine to queue up again for more questions. The next question comes from Jakob Lemke from SEB. Please go ahead.

Jakob Lemke
21:24 - 21:51

Yes. Hi. Good morning. My first question is on the gross margin. You mentioned regional mix here during the call. I just want to clarify that. Is this mainly related to the sort of different business mix you have in the regions, or are there anything else behind that in the regional mix? And then also, if you could give an indication of whether 58-59% gross margin is a new normal we should expect going forward.

Pär Ihrskog
21:52 - 22:18

Yeah. On the gross margin, as we explained, it's a big impact from currency. But also partly it's regional mix. It is a negative impact, but its effect is less compared to the currency impact. And it's very much driven by the growth in the US. Yeah. And what was the second part of your question.

Jakob Lemke
22:20 - 22:30

Given the moving parts, is the range between 58% and 59% on the gross margin something we should expect going forward?

Bronwyn Brophy O’Connor
22:32 - 23:59

Yeah, I can take that one. And maybe just to add one point to Pär's point just on the gross margin, Jacob, because I know you know us very well. So there is a regional mix effect. Pär is spot on there with the US growth. I guess everybody knows that one. There is also a mix effect within consumables in APAC. So you can see that there. In terms of what you can expect going forward. Q4 last year wasn't normal. It was abnormally good. I think we will return to more normal levels more and more in the sort of 59 percent range. We're not expecting the mix effect to be this extreme as we move through 2026. We're also working on initiatives to improve our profitability in North America. As you know, North America has a big component of Genetic Services. But obviously, the more we can increase Technologies penetration, EmbryoScope, and share gains on the Consumables side, that helps. So, this quarter we're comparing two extremes, if you like, but we expect to return to more normal gross margin levels in 2026. Does that help? To answer your question, without me revealing too much? Is that okay, Jacob?

Jakob Lemke
24:00 - 24:31

Yeah. That's very clear. Then my follow up question is just on trying to understand the admin costs here in Q4. Because you had sort of surprise high admin costs in Q4 last year, and now they're also looking quite high when we disregard one of those. What is really behind that, and what do you expect for costs related to the legal process in the US for 2026?

Pär Ihrskog
24:33 - 25:35

Within the administrative costs, we include IT. And then we have other support functions like finance, HR, legal, and IT spend, as we have communicated. IT spend has also increased somewhat in previous quarters as we invest in our IT capabilities. That increase in IT that we see in the last couple of quarters in Q4, has been partly offset by reduced admin costs in other areas such as finance, legal, and HR. Yeah. So this level you see right now is the underlying base. We have also communicated in December a restructuring program, where we are looking at reducing admin costs and selling costs in 2026.

Jakob Lemke
25:39 - 25:45

Because you had surprisingly high admin costs in Q4 last year, and now they're also looking quite high when we disregard one of those. And if you could comment on expectations for legal costs, maybe for 2026?

Pär Ihrskog
25:46 - 25:55

We have not made any reservation for legal costs relating to the class action in the US. And we don't plan to either. We don't see the need for that.

Jakob Lemke
26:00 - 26:00

Because you had surprisingly high admin costs in Q4 last year, and now they're also looking quite high when we disregard one of those. Because you had surprisingly high admin costs in Q4 last year, and now they're also looking quite high when we disregard one of those.

Bronwyn Brophy O’Connor
26:02 - 26:03

Because you had surprisingly high admin costs in Q4 last year, and now they're also looking quite high when we disregard one of those. Jacob.

Operator
26:05 - 26:10

The next question comes from Ulrich Trattner from DNB Carnegie. Because you had surprisingly high admin costs in Q4 last year, and now they're also looking quite high when we disregard one of those.

Ulrich Trattner
26:12 - 26:35

Good morning, and thanks for taking my questions. I'd like to dig a little deeper into this IT investment you're doing. If you can provide us with some more specifics on what it actually is. How big are these investments and for how long do you expect to invest into essentially the back end of your business?

Bronwyn Brophy O’Connor
26:37 - 26:38

I can take this one part.

Bronwyn Brophy O’Connor
26:39 - 28:07

So, IT investments going into two key areas. Ulrich. The first part is on the customer-facing customer journey, digitalizing how we interact with clinics, but also with patients. And this is a key enabler of driving growth, particularly in North America, but also increasingly in Western Europe. So I would say that's category one. We're also making investments in IT that will allow us in time, and it will take time, to improve our efficiencies. So that can be, you know, efficiency in lab operations. Things like LIMS, obviously, when you're running a services business, you don't have to have the best of every system, but you want to be able to drive efficiency and also scale. So apart from the customer journey, the other investments are going into, I guess, what I would call backbone investments. Now again, we have to be pragmatic here. They need to be linked to driving growth. And we're not expecting to be best in class in everything related to it. But we do believe there is a need to make investments in order to support our growth ambitions. Does that answer your question, Ulrich?

Ulrich Trattner
28:08 - 28:29

Sure. Yeah. And, just to clarify, so it sounds like there's not IT investment into products. It's more customer-focused, more in sales and marketing IT infrastructure rather than IT investment into products.

Bronwyn Brophy O’Connor
28:30 - 28:59

Yeah, I think that's a fair comment. As you know, as part of our R&D program, we have openly stated that we are aiming to build an end-to-end IVF platform. So there are some digital investments there, but the vast majority are going on the customer sales and marketing side, either for driving growth or helping us to improve efficiency. So yes, you're correct with that assumption.

Ulrich Trattner
29:01 - 29:23

Great. And just a follow-up question on the general OpEx and quantification of FX effect on EBITDA. If you were able to give us some hint on the quantification of the negative FX effects here for Q4. Like we know that the topline effect here, but how big was the effect on EBITDA?

Pär Ihrskog
29:24 - 29:36

Yeah. All in all, the effect on EBITDA margin is approximately 2.5 percentage points, affecting EBITDA margin negatively.

Ulrich Trattner
29:38 - 29:42

Great. Thank you. And I'll get back into the queue.

Bronwyn Brophy O’Connor
29:43 - 29:43

Thanks, Ulrich.

Operator
29:46 - 29:51

The next question comes from Sten Gustafson from ABG Sundal Collier. Please go ahead.

Sten Gustafson
29:53 - 30:07

Good morning. First of all, clarification or maybe confirmation. Did you say that the adjusted contribution margin for the EMEA region was 36.4% in the quarter?

Bronwyn Brophy O’Connor
30:15 - 30:25

Adjusted margin. Can you repeat the question, Stan? Yes. Can you repeat the question, Sten? Sorry. You just went out at the critical moment.

Pär Ihrskog
30:26 - 30:26

Yeah.

Sten Gustafson
30:27 - 30:33

I think you mentioned the adjusted contribution margin in the EMEA region.

Pär Ihrskog
30:35 - 30:38

Yeah, it is 36.4%.

Sten Gustafson
30:39 - 31:00

Okay, great. So my question is, what exactly are you restructuring in the EMEA region and how should we think about will there be savings coming out of that or what exactly have you done in the region?

Pär Ihrskog
31:02 - 31:47

This restructuring is connected to the announcement we made in December related to the genetic services business. We are stopping providing two product lines. It's the NASA and GDP. And we are also exiting some markets. And so, of course, that affects the whole company but has a larger effect on this region compared to the other regions. So, to a large extent, the restructuring cost is related to people affected by this restructuring action.

Bronwyn Brophy O’Connor
31:47 - 32:19

Yes. Perhaps to explain it a slightly different way, Sten, we announced the restructuring, as Pär mentioned in December, and the region that's most impacted by that restructuring is EMEA. The reason why EMEA is the most impacted region is because most of the NIPT and GDP revenue was in that region, and most of the markets that we will be exiting are within the region. So that's a slightly different way to explain it. Does that answer your question?

Sten Gustafson
32:20 - 32:37

Absolutely. That clarifies a lot. And I do remember, you announced it and we were discussing different potential cost savings coming out of it. So it all makes sense. Thank you very much. I'll get back into the queue. Thank you.

Unknown 1
32:38 - 32:39

Thank you. Stan.

Operator
32:41 - 32:46

The next question comes from Ludwig Gemunder from Handelsbanken. So we exited that market in December 2024.

Ludwig Gemunder
32:47 - 33:10

Yes. So we exited that market in December 2024. Good morning. And thank you for taking my question. So I'll stick to the one question. And it's about the organic growth that you reported, I think 3%, but 6% excluding discontinued businesses. Would you be willing to help us understand the phase out of the products? For how long will the tests continue to be a part of your sales, and when do you expect the phased out products to be fully phased out?

Pär Ihrskog
33:12 - 33:40

This discontinued business doesn't relate to the exiting of these two product lines. This relates to the exiting of a market, announced last year or December 2023, while the exiting of product lines that we announced last December is taking place right now. We expect it to be finalized in Q1.

Bronwyn Brophy O’Connor
33:42 - 34:51

Most of it should be. Most of it should be. Sorry. Just one correction. So, we exited that market. I think most people know which market it is. So we exited that market in December 2024. So we had the full 2025 having to explain organic growth in local currencies, excluding discontinued business. And it was because of that exit of that sizable market in Q4 2024. With the restructuring that we announced in December, our goal is to essentially be fully out of those tests and most of those markets. By the end of the first half, we have set ourselves an accelerated target on that. So in certain instances, we'd like to be done and dusted by the end of Q1. But our commitment in that announcement is by mid-year. Does that help? To answer your question, just to make sure we're not confusing a previous market with the current. Yeah. And there are a lot of details here, so I do apologize. Yeah.

Ludwig Gemunder
34:53 - 35:06

Thank you for clarifying. And just to follow up on that, do you expect the organic growth, which was 6%? Now do you expect that growth to continue to be around that growth rate over the next year? How should we think about the future?

Bronwyn Brophy O’Connor
35:07 - 36:54

I don't like to guide and I don't like to guess. The only thing I can say to you is that we are expecting market conditions to return to more normal levels. Last year wasn't normal in any shape or form. We had a big APAC effect in Q1. We had a tightening US administration effect in Q2 and Q3. So we do expect more normal market conditions this year. What, I guess, does more normal mean? There are big regional variances now, as you can see. But what we've decided to do as a company is double down where the growth is and obviously protect what we have. Where the growth is, it is a little bit slower. So I don't want to guide. All I will say is that we, and I hear the same from some of our competitors' transcripts. I think as an industry, we're expecting more normal market conditions this year. The key thing for us is not just driving growth. It's driving profitable growth. So, a big focus this year is on ensuring that we get the right portfolio balance in the regions. I think North America is doing fantastically well. We're really happy that the investments there are paying off, but we need to continue to drive EmbryoScope penetration. We need to continue to take share gains in consumables. So I don't want to guide, I'm not going to fall into the trap, but hopefully I've given you more color around how we see things in 2026 and more of a return to normality. But again, it's got to be about profitable growth.

Ludwig Gemunder
36:56 - 36:58

Yeah. The next question comes from Ludvig Lundgren from Nordea. I'll get back into the queue.

Bronwyn Brophy O’Connor
36:59 - 37:01

We're really happy that the investments there are paying off, but we need to continue to drive EmbryoScope penetration. Thanks, Rick.

Operator
37:04 - 37:08

The next question comes from Ludvig Lundgren from Nordea. Please go ahead.

Ludvig Lundgren
37:10 - 37:28

Yes. Hi. And thank you for taking my questions. So I wanted to start off a bit on the same theme here on the IVF market environment. And I think in Q3 you highlighted that you saw a pickup in cycles towards the end of the quarter. So I just wonder how this has tracked throughout the quarter. And into January here. Has it continued to improve basically.

Bronwyn Brophy O’Connor
37:29 - 40:24

Yeah. Good question. So, as I mentioned before, we didn't sort of see an explosion of pent-up demand in North America following the announcement from the White House in October. But we did see a steady pickup in the cycle growth in the final weeks of the quarter. And that seems to be continuing into Q1. It's very early to say, I haven't even seen our full January numbers yet, but I was at JP Morgan. I spent a lot of time visiting customers as well in the US, and the sentiment seems to be better. What I would say is that the announcements that were made in relation to very significant price reductions. Everybody now realizes that that's not the case. But there's clarity now in the US in terms of what the cost of a cycle is going to be. There are other things like California becoming a mandated state. That's something that was delayed for, for quite a while. So, it's one state within the United States, but it's a big one. So I think there's a little more optimism in California in particular in terms of of cycle rates, slowly but surely, picking up as we advance through through 2026. And then I don't want to make it all about North America. How do we feel about the rest of the world? Western Europe is looking. Good and steady. And cycle growth seems to be again approaching more normal levels. The Middle East has experienced a significant impact due to the geopolitical situation there. And then as we view APAC, I've commented many times, we believe that there are. Endemic issues in China in relation to improving the birth rate and the cycle growth. But. The government is also increasingly stepping in and approving funding. There are opportunities in other parts of Asia which I'm not going to go into for competitive reasons. Normal growth rates are returning, we expect. But there will be regional differences. And I think the key thing for us, back to the point that I made on our commercial excellence capabilities, we're really getting laser focused in terms of where we're doubling down and where we're not going to double down. So where do we see the greatest opportunities to drive profitable growth? Does that answer your question, Ludwig? I don't want to be going around the world giving my prognosis, but that's how we see things at a corporate level.

Ludvig Lundgren
40:26 - 40:43

Yes. Very clear. But there's clarity now in the US in terms of what the cost of a cycle is going to be. And then I just had a follow-up on the gross margin in APAC here. So you highlighted that there was some negative product mix from campaigns, I believe. So I just wonder if it's possible to quantify this in some way. Will this also affect Q1 and Q2 in 2026?

Bronwyn Brophy O’Connor
40:45 - 41:00

I can take the second part. No, we expect the margins in APAC to normalize in 2026. I don't know, Pär. In terms of quantifying the mix, we probably can't divulge that.

Pär Ihrskog
41:00 - 41:11

We don't disclose the detailed effect, but it had an impact not only on APAC, but also on the total gross margin for the group. But we don't disclose the number.

Bronwyn Brophy O’Connor
41:14 - 41:47

What I will say is it was a strategic decision to go after a growth opportunity. So it was a targeted campaign. 10% growth in APAC. I don't think anybody expected that it surpassed our expectations, but I think it surpassed our expectations more on the technology side, on the consumables. We very much decided that we had an opportunity to take share in disposable devices. And we went for it. Yes.

Ludvig Lundgren
41:49 - 42:00

Yes. And just very quick on that. When you have gained some share now in Q4 in APAC, will that also improve growth ahead in APAC? That's a reasonable assumption.

Bronwyn Brophy O’Connor
42:01 - 42:53

That's what we're trying to do. APAC has been pretty stagnant for a lot of the reasons that I've mentioned. The market growth in APAC is pretty stagnant. But we believe we had an opportunity to take share from a couple of competitors in relation to a specific part of the portfolio. So, yeah, we went for it. Will that continue in 2026? Taking that magnitude of share, that will be tough. But we do have the share gain momentum. So it should definitely improve our disposable device performance in APAC in 2026. Does that make sense without me giving away too much information? Hopefully I'm helping to answer your question.

Ludvig Lundgren
42:54 - 42:58

Yes. Very clear. I think you referred to some insourcing. I'll jump back into the queue.

Bronwyn Brophy O’Connor
42:58 - 42:59

I think you referred to some insourcing. Thank you.

Operator
43:02 - 43:07

The next question comes from Johan Aneris from SB1 Markets. Please go ahead.

Johan Aneris
43:09 - 43:34

Thank you for taking my question and congratulations on the progress made in the US market, especially as you are investing in commercial reach there. My first question relates to gross margins. First, the small one. I think you referred to some insourcing. Does that have an impact on margins in that region? Now, for my second question.

Bronwyn Brophy O’Connor
43:36 - 46:21

So, good morning, Johan. Thank you for your compliment on North America. We're going to take it graciously. And because we are very pleased with our North America, and I think we should bear in mind it's only two years ago that we decided that we were going to go after growth in North America, and to be seeing the returns after only having made those investments not so long ago is pleasing to us now. We're not losing the run of ourselves. We have a long way to go, but. But we are pleased with the progress there. So, let's touch EMEA. So what has happened in the EMEA region? Actually, it's probably best explained in my CEO comments. And that is with the downturn in activity due to the geopolitical situation in the Middle East, what we have seen is that clinics have in-sourced some of their genetic services business. And we have seen historically when clinics insource, we saw this in North America three years ago. Typically, the business you might get drip feeds of it coming back. But it's rare that you get all of that genetic services business back. So clinics, in an endeavor to boost their revenues, have insourced; they've taken the opportunity to insource — the impact on margins. That's a good question. It's also a tough question. It's not necessarily a negative thing because the margins in genetic services are lower versus the rest of the portfolio. So they're lower than technology and consumables. So it doesn't necessarily imply a negative margin mix in the region. What we do need to do in this region is we have to make up for that lost business. Right? So we have to drive share gains across the rest of the portfolio, and we have to drive share gains in the other markets in the region. I think we're particularly happy with the consumables portfolio performance in EMEA. So you can see on page 22 of the report, it's 11% organic growth in local currencies. So that's good. Technologies, very tough quarter. But if we can move the needle on technologies there, the run rate on technologies is doing very well. That will also help the EMEA margin mix. So it's a very long explanation to your question, Johan, but there are quite a few moving parts on that one. But hopefully I'm giving you context there. Yes. So you can see, on page 22 of the report, it's 11% organic growth in local currencies.

Johan Aneris
46:21 - 46:51

So you can see on page 22 of the report, it's 11% organic growth in local currencies. It's not necessarily a negative thing because the margins in Genetic Services are lower versus the rest of the portfolio. And then perhaps the more important question on the US, it's often easier to improve gross margin when you have better traction, as you seem to have. But the process of improving gross margins, changing products, and perhaps working on efficiencies as well, as you alluded to. Could you provide any timelines on those dynamics?

Bronwyn Brophy O’Connor
46:52 - 48:29

Pär, you can chip in here as well. But the investments in sales and marketing, they're done now. We don't envisage making any further investments in sales and marketing. I would say they're fully loaded. So now we have to drive productivity, right? So the revenue per commercial investment, the revenue per sales rep, that needs to go up. We made those investments. It's taken time. But we would expect productivity improvements in terms of revenue generation coming out of those commercial investments. There is a mixed component. And we are really focusing on EmbryoScope and Witnessing. This is evidenced by the 40% growth in the quarter. We're going to keep doubling down there. I think what we like is that clinic chains are increasingly seeing the workflow benefits from EmbryoScope. It's a big capital outlay, but it also drives efficiency. So that's good. And then Johan, we have to look at pricing. We're still operating in an inflationary environment. We can't carry those costs. So inevitably, the team did a very good job in North America last year on pricing. We managed to mitigate a significant amount of the tariff impact. But inflation is still there. And we will have to look at pricing opportunities actually in all of the regions. Pat, is there anything I can add?

Pär Ihrskog
48:30 - 49:02

Maybe I can just add, we have made our investments in the US. We don't intend to increase the level. We will. We have done our work now. So now we have this fixed cost there. And we aim for further growth in North America. And if that happens, of course, the contribution margin will gradually improve if we continue to see growth in North America or Americas and keep the OpEx level constant, which is our plan. Yeah.

Johan Aneris
49:04 - 49:19

And then, in a sense of the effect on gross margins, should we expect improved gross margin in the Americas, especially in the US market? 26 or could you provide some flavor on that?

Bronwyn Brophy O’Connor
49:22 - 50:20

With everything fully loaded, our aim and our goal is absolutely to improve the gross margin in North America. I'm sticking my neck out here. You're going to track me on that metric. But that's what we have to try to do, right? It's very clear in the numbers in this quarter. We've had a fantastic performance on the top line. North America is doing great and APAC did wonderfully well. But we have to work on the margin piece because we don't want Americas to become dilutive overall. So absolutely, the strategic name of the game and where we're doubling down is on the areas where we can improve the margin from what is becoming our fastest growing region. And it's the largest IVF market in the world. So we want to win there. But we want to win there. Driving margin improvement. Does that answer your question? Okay.

Johan Aneris
50:20 - 50:21

Yeah. Sort of.

Unknown 2
50:22 - 50:23

Okay.

Bronwyn Brophy O’Connor
50:23 - 50:32

Hello, everybody. Do you want to try asking it a slightly different way, and I can see if I can answer better. Yeah. What are you missing?

Unknown 2
50:33 - 50:34

Yeah.

Johan Aneris
50:34 - 50:48

No, I'm pleased. I understand the complexity. Of course, it's difficult to provide precise feedback for 2026. Yeah, I can see the work in progress.

Bronwyn Brophy O’Connor
50:49 - 50:53

Yeah, exactly. Thanks, Johan.

Operator
50:57 - 51:01

The next question comes from Philip Einarsson from Redeye. It's very clear in the numbers in this quarter.

Ulrich Trattner
51:04 - 51:27

Okay. Hello, everybody. So I wanted to start on something you mentioned both in the call and also in the report, namely the market normalization in 2026. Maybe if you could expand a little bit on this statement and to what extent you expect this to be gradual? So I wanted to start on something you mentioned both in the call and also in the report, namely the market normalization in 2026.

Bronwyn Brophy O’Connor
51:27 - 53:46

Yeah, great. Great question. Historically, cycle growth has been in the mid-single-digit range. That was not the case in 2025. Based on our best intelligence. And we are very close to the market, but you can also hear it in the competitive commentary and on the clinic side, the cycle growth was significantly impacted in 2025 for a multitude of reasons, which I'm not going to bore everybody with by repeating it. I absolutely hate going back to this zodiac thing, but we don't have snakes or dragons this year. Hopefully we don't have presidential statements on IVF. They're done. They're past us. So that created a lot of noise. The situation in the Middle East seems to be holding up. Western Europe is looking pretty stable. Cycles are definitely returning to more normal levels there. So, you know, we're not getting very excited in terms of an explosion in IVF cycles. That's absolutely not happening. But based on Q4 early indicators. And again, we've really become laser focused on steering Vitrolife AB in a metric driven way, particularly on the commercial side. And the leading indicators there do point to more normal cycle levels. The second part of your question then is how quickly do we get there? How long is a piece of string that's a little bit harder to predict, I guess. Well, I don't guess; what we envisage in our company is a slow, steady return to more normal levels, but regarding when we get there, should it be in Q1, or perhaps Q2? I mean, unless we have some big disturbances, we would be expecting to get back to those more normal levels in Q2. Does that answer your question?

Ulrich Trattner
53:47 - 54:13

Yes. Yeah. So I wanted to start on something you mentioned both in the call and also in the report, namely the market normalization in 2026. And then I have one more follow up. Can you maybe elaborate a little bit on if there's any measures taken to limit the impact in 2026, given eventual ongoing uncertainty on the macroeconomic level? Obviously, currency has been a big topic in 2025 and in Q4. Can you elaborate a little bit on if there are any measures taken to limit the impact in 2026, given eventual ongoing uncertainty on the macroeconomic level?

Pär Ihrskog
54:15 - 55:28

And you mentioned challenges in China. Currency has had a huge impact on us and on many Swedish companies with exports, just to give you a flavor of it. The US dollar's impact should be considered separately. You probably know this, but the SEK strengthened almost 17% last year from 1st of January to the end of December, and the euro was more like seven to eight percent. And the Danish krona, which is also an important currency for us, was also some 8%. Japanese Yen was 14%. So we had a huge currency impact. So what do we do? We don't really know what happens. We don't work with hedging in our company. What we are trying to do better is to increase our natural hedge by balancing purchases in certain currencies, matching the revenue stream. This takes time. So I don't expect us to fix that in a short while. But this is something we need to increase our focus on going forward to improve our natural hedge.

Ulrich Trattner
55:31 - 55:34

Can you elaborate on if there are any measures taken to limit the impact in 2026, given eventual ongoing uncertainty on the macroeconomic level? That helps. Can you maybe elaborate a little bit on if there's any measures taken to limit the impact in 2026, given eventual ongoing uncertainty on the macroeconomic level? Did you have positive sales growth in China?

Operator
55:37 - 55:42

The next question comes from Sten Gustafson from ABG Sundal Collier. The next question comes from Sten Gustafson from ABG Sundal Collier.

Sten Gustafson
55:43 - 56:09

Hi. Thanks for taking another question. Going back to the very strong performance in Asia or APAC region, 10%, obviously very impressive. And you talk about tough in China. Did you have positive sales growth in China? Despite the soft market.

Unknown 2
56:12 - 56:14

Yeah, we we.

Bronwyn Brophy O’Connor
56:14 - 57:09

We don't give country breakdown, but maybe the best and fairest way that I can answer that question is that we had growth in almost all countries in the APAC region in Q4. Even so. So, on the technologies piece as well. Sten. It was a tough year for capital purchases, but we saw a release of budgets, and it was literally in the final couple of weeks of the year. Fortunately, we had enough EmbryoScope in stock to be able to service the demand. Because it was quite an uptick in the last three weeks. But it was. I'm not going to answer country-specific, but I will tell you, most of the countries in APAC had a positive performance in Q4.

Unknown 2
57:10 - 57:10

Yeah.

Sten Gustafson
57:11 - 57:20

Sounds good. And any country doing extremely well, unusually well? Or was it more across the board?

Bronwyn Brophy O’Connor
57:20 - 58:33

No, I don't think there was any sort of extreme. No, I don't think there was any sort of extreme. So, we did have a targeted campaign on disposable devices. We saw an opportunity to take share from competitors. And, Sten, you know us very well, media. We've already taken a lot of share in media in APAC. So share gain opportunities are much tougher to come by. So we've been looking at APAC as part of our strategic review. And we said where do we have opportunities to take share. We can't continue to grow with the market. And we identified disposable devices as a double down. So we went for that across the region. And then the other big needle mover was we still believed there were opportunities on the EmbryoScope side, even though clinics were managing the capital piece. And then when they were released, we were able to capitalize on that. And we don't have the sort of genetics component here. But so, no, there was no explosion in any one particular country.

Sten Gustafson
58:34 - 58:42

Sounds good. 10% is an impressive number, given the softness in China. So.

Bronwyn Brophy O’Connor
58:43 - 58:47

No, absolutely. Thanks very much, Stan. 10% is an impressive number given the softness in China.

Sten Gustafson
58:47 - 58:48

But, no, there was no sudden surge in any one particular country.

Operator
58:50 - 58:54

The next question comes from Jakob Lemke from SCB. Please go ahead.

Jakob Lemke
58:58 - 59:07

I just had a short follow up. Just on technologies. Technologies? In North America, if you can elaborate on what countries, what customers, and so on.

Bronwyn Brophy O’Connor
59:08 - 61:26

Yeah. This is my favorite question, Jakob, because we had 40% growth in Americas. It was across the region. I think what pleases us most here is that we are starting to crack into the chains, and we came very close, very, very close to having one of the largest cross-border chains in North America going full EmbryoScope. I think we were two EmbryoScopes short of a particular chain being fully converted. Fully converted EmbryoScope. And that's been tough for us, right. Because historically in North America, we've been able to sell one-off EmbryoScopes, but we weren't really cracking the chains. And you can understand why. I mean, they're big. They're a big investment. That started to happen. It started to happen last year. We've adapted our go-to-market model. We now focus on key accounts. Key account manager style. So we have people specifically targeting and talking to the c-suites of the large clinic chains, and it's paying off. So what drove that big 40% increase is we're starting to move the needle on EmbryoScope in the chains. It's been a heavy lift, but we're getting there now. I think very importantly, as I always say to the team, don't just sell EmbryoScopes. You have to make sure that they get used. So the other metric that we're tracking back to our commercial excellence dashboards is we're checking the revenue generated per EmbryoScope. So we don't just want clinic chains investing in EmbryoScope. We want them investing and using them to drive efficiency. And we're starting to see the run rate in Technologies. That component is picking up very nicely. But it's all markets in Americas, but I should give a shout out to North America because I think the team did a really great job there. Does that answer your question?

Jakob Lemke
61:26 - 61:26

And on genetics in EMEA and insourcing.

Bronwyn Brophy O’Connor
61:27 - 61:27

Yeah.

Jakob Lemke
61:27 - 61:29

Yeah. That's great. But is it possible to quantify the risk of continuous insourcing, as we did see in the Americas 2 or 3 years ago?

Operator
61:32 - 61:36

The next question comes from Ulrich Trattner from DNB Carnegie. But that started to happen.

Ulrich Trattner
61:39 - 61:40

And on genetics in EMEA and in insourcing.

Ulrich Trattner
61:40 - 62:08

And on genetics in EMEA and insourcing. And as you noted, you don't expect these share losses to be regained, given that they've gone internal. But is it possible to sort of quantify the risk of continuous insourcing, as we did see in the Americas 2 or 3 years ago? Or is this more temporary, like related to the macro, or is this a continuous trend?

Bronwyn Brophy O’Connor
62:09 - 63:03

Yes, it's a great question. Ulrich. The ones who have in-sourced are the larger ones. So I never like to be complacent. Let's see if the Middle East is able to do it more efficiently or better. And we don't take any customer or any business for granted. And we have to earn our crust every single day. But the customers that have in-sourced in the second half of 2025 are the bigger ones. So I want to be really clear. I wouldn't call it share losses. It's definite in-sourcing; we can see it. We know the clinics. We have the names. We know the players, as in people working there. So I think the biggest impact is likely behind us. Ulrich.

Ulrich Trattner
63:04 - 63:04

Okay.

Bronwyn Brophy O’Connor
63:05 - 63:53

And again, we've seen this with insourcing in North America. It doesn't always. Well, first of all, it's not as easy as people think. In any services, business scale is important. Economies of scale are very important. And I think a lot of clinics that did insource, particularly in North America, didn't get the type of gains that they expected. Let's see if the Middle East is able to do it more efficiently or better. But it hasn't always paid off. The insourcing. Yeah. I thought you were going to ask me a question.

I was waiting for it. Okay. Thank you.

Ulrich Trattner
63:54 - 63:54

Thank you.

Bronwyn Brophy O’Connor
63:55 - 64:11

I think we're finished now. I'd like to thank you all for your time and attention this morning for your great questions. We very much appreciate it. So from Stockholm, from myself and Pär and from Emily Wilson in Investor Relations, thank you all very much and have a wonderful day.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…